KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adient (ADNT) Liabilities and Shareholders Equity (2016 - 2025)

Adient (ADNT) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $8.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 2.82% year-over-year to $8.8 billion, compared with a TTM value of $35.2 billion through Dec 2025, down 3.04%, and an annual FY2025 reading of $9.0 billion, down 4.25% over the prior year.
  • Liabilities and Shareholders Equity was $8.8 billion for Q4 2025 at Adient, down from $9.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $10.8 billion in Q3 2021 and bottomed at $8.5 billion in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $9.4 billion, with a median of $9.3 billion recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity increased 5.04% in 2021, then fell 15.03% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $10.7 billion in 2021, then fell by 13.49% to $9.3 billion in 2022, then increased by 0.26% to $9.3 billion in 2023, then decreased by 8.22% to $8.5 billion in 2024, then increased by 2.82% to $8.8 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ADNT at $8.8 billion in Q4 2025, $9.0 billion in Q3 2025, and $8.8 billion in Q2 2025.